

# Correlates of one-year mortality among patients living with HIV according to the stratification level of the pharmaceutical care model.

Abstract Number: 6ER-008



Enrique Contreras Macías<sup>1</sup>, Francisco A. Lao Domínguez<sup>2</sup>, Patricia García Lloret<sup>2</sup>, Ramón Morillo Verdugo<sup>2</sup>

<sup>1</sup>Pharmacy Department, Hospital Infanta Elena, Huelva, Spain.

<sup>2</sup>Pharmacy Department, University Hospital Virgen De Valme, Seville, Spain.

Contact: [enrique.contreras.macias.sspa@juntadeandalucia.es](mailto:enrique.contreras.macias.sspa@juntadeandalucia.es)

## BACKGROUND & IMPORTANCE

- The **success of highly active antiretroviral (ARV) therapy** has allowed people living with HIV (PLWH) to have a **near-normal life expectancy**.
- The increase in life expectancy has generated a **new set of challenges** in these patients, who often experience **age-related comorbidities** and, with it, **polypharmacy** with the negative consequences.


## AIM & OBJECTIVES

- To analyze the **effect that the level of stratification has on mortality** results at one year and develop a predictive model in PLWH on active ARV.

## RESULTS

- A **total of 427 PLWH** were included; 352 (82.2%) Males. **Three PLWH were lost to follow-up**, 2 of them due to a change in hospital center and 1 due to abandonment of follow-up by both the doctor and the pharmacist.
- The **distribution of patients according stratification model** was: level 3 (83%), followed by 12% and 5% for level 2 and 1, respectively.
- The **clinical variables determined prior to the death** of the patients show that more than half had undetectable viral load (80%) and CD4+ >200 cell/mm<sup>3</sup> count (60%).
- The **overall mortality rate from any cause in our population was 11.7 per 1000 PLWH**. Causes of death in PLWH were cardiovascular disease (n=2), cancer (n=1), pneumonia (n=1) and acute respiratory failure (n=1). Survival function shown in figure 1.
- If we focus on **clinical variables**, the Long-Rank test found significant differences in those patients who suffered from **type 2 diabetes mellitus** (p=0.04) and **arterial hypertension** (p=0.04) compared to those without a diagnosis of these diseases.
- When using the Long-Rank test to compare the **level of stratification**, we found significant differences in the proportion of deaths (**p=0.02**).
- In a multivariable Cox proportional hazard model that included the **stratification level was associated with a higher mortality** whose **level 1 patients had a 99.7% higher mortality** (HR: 0.0003; 95%CI: 0.001-0.027; p<0.01) and **level 2 patients had a 22% higher mortality** (HR: 0.078; 95%CI: 0.01-0.58; p=0.02) than patients classified in level 3. **The AUC-ROC was 0.98** (95%CI: 0.96-1.00). ROC curve shown in figure 2.

Figure 1. Overall survival curve based on the level of stratification.



## METHODS


- A single-center, cross-sectional study that included **PLWH on active ARV** who attended Pharmaceutical Care outpatient between January 1 and March 31, 2021 and were **followed up for a period of 1 year**.
- Demographic, clinical, pharmacotherapeutic variables pharmaceutical care, level of stratification (**according to HIV patient model published by SEFH<sup>1</sup>**) were collected (*Table 1*)
- A **survival analysis** was performed to assess how the **level of stratification predicted mortality at one year**. The survival rate was estimated using Kaplan-Meier and differences between levels were evaluated using Log-Rank test.
- A **Cox regression** was run to estimate hazard ratios. To evaluate the discriminatory power of the model, the calculation of the area under the ROC curve (AUC-ROC) was carried out.

Table 1. Baseline characteristics

Characteristics	Entire Cohort (n=427)	N1 (n=17)	N2 (n=43)	N3 (n=367)	P Value <sup>a,b</sup>
Median age, y (IQR)	51 (42-57)	51 (47-58)	55 (52-58)	51 (51-53)	0.24 <sup>c</sup>
Male sex	352 (82.2)	12 (70.6)	33 (76.7)	306 (83.4)	0.09
Comorbidities					<b>0.01</b>
Depression	37 (8.7)	1 (5.9)	4 (9.3)	32 (8.7)	0.91
Dyslipidemia	79 (18.5)	4 (23.5)	8 (18.6)	67 (18.3)	0.86
Diabetes mellitus type 2	33 (7.7)	0 (0)	7 (16.3)	26 (7.1)	<b>0.04</b>
High blood pressure	86 (20.1)	7 (41.2)	11 (25.6)	68 (18.5)	<b>0.04</b>
Polypharmacy	111 (25.9)	2 (11.8)	16 (37.2)	38 (10.4)	0.91
ARV type					0.14
NRTI + NNRTI	43 (10.0)	1 (5.9)	4 (9.3)	38 (10.3)	
NRTI + PI	60 (14.0)	2 (11.8)	5 (11.6)	53 (14.4)	
NRTI + INI	212 (49.4)	8 (47.1)	18 (41.9)	185 (50.3)	
Others	114 (26.6)	6 (35.3)	16 (37.2)	92 (25.0)	

<sup>a</sup>P value compares patients stratified according model risk-stratification of patients for pharmaceutical care in patients with HIV of the Spanish Society of Hospital Pharmacy.  
<sup>b</sup>X<sup>2</sup> test unless otherwise specified.  
<sup>c</sup>T-test used to calculate P value.

Figure 2. ROC curve for predictive mortality regression model



AUC	SE	Signif	95%CI lower limit	95%CI Upper limit
<b>0.982</b>	<b>0.011</b>	<b>0.001</b>	<b>0.961</b>	<b>1.000</b>

## CONCLUSION & RELEVANCE

- Our study showed that In this cohort of PLWH outpatients, **overall mortality of one year differs when comparing the pharmaceutical care stratification**, despite being similar in age and other clinical conditions.
- This suggests that **the multidimensional stratification tool**, included in the CMO pharmaceutical care model, could be used to modulate the intensity of patient follow-up and design interventions more tailored to their needs, in order **to improve their health status and quality of life**.



Consulta de Atención Farmacéutica  
Patologías Viricas

1. Morillo-Verdugo R, Martínez-Sesmero JM, Lázaro-López A, Sánchez-Rubio J, Navarro-Aznárez H, De Miguel-Cascón M. Development of a risk stratification model for pharmaceutical care in HIV patients. Farm Hosp. 2017; 41(3):346-356. doi: 10.7399/fh.2017.41.3.10655